GlobalData on MSN18h
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
In vitro model enables study of age-specific responses to COVID mRNA vaccines
RNA vaccines saved lives during the COVID-19 pandemic, but older people had less of an immune response to the vaccines than ...
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
Study reveals COVID-19 vaccine safety in patients with atrial fibrillation/flutter
Development of the coronavirus disease 2019 (COVID-19) vaccine has been key to countering the pandemic caused by severe acute ...